

2019年昆明国际动物学研讨会

会议手册





2019年7月24日

云南·昆明



2019






77 0871-68211257

kongyanjie26@163.com

5







Mien-Chie Hung
洪明奇

Ph.D. is the President for China Medical University in Taichung, Taiwan. He was vice president for basic research and professor and chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center. He received undergraduate and graduate degrees from the National Taiwan University and his PhD from Brandeis University. After completing postdoctoral training with Dr. Robert A. Weinberg at the Whitehead Institute/Massachusetts Institute of Technology. Dr. Hung was recruited to MD Anderson in 1986. Dr. Hung is internationally recognized for his studies of signal transduction pathways regulated by tyrosine kinase growth factor receptors, such as EGFR and HER-2/neu, as well as molecular mechanisms of tumorigenesis. Up to date, Dr. Hung has published more than 525 peer-reviewed articles, of which over 130 were published in journals with impact factor 10 or above. His lifetime h-index surpasses 110. Dr. Hung has served in many study sections of the NIH and various funding agencies in many other countries to select awardees. He is one of members of Selection Committee for Tang Prize in Biopharmaceutical Science category and 2016 Pezcoller Foundation-AACR Award.


Dr. Hung also serves as an editorial member for many journals in cancer research to evaluate quality of submission. Notable, he is one of the founding Editorial Members for Cancer Cell, serves as Editor-in-chief for American Journal for Cancer Research (2015-2017) and Senior Editor for Cancer Research (American Association for Cancer Research, 2018-2021). Dr. Hung was inducted as an Academician of the Academia Sinica in Taiwan in 2002. In addition, Dr. Hung was selected as a Fellow in Biological Sciences section, American Association for the Advancement of Science (AAAS Fellow) in 2010. He served as President for the Society of Chinese Bioscientists in America (SCBA) from 2004-2005 and is also the recipient of SCBA's Presidential Award in 2011 and Lifetime Achievement Award in 2017. In addition, Dr. Hung was awarded with The University of Texas MD Anderson Cancer Center LeMaistre Outstanding Achievement Award in 2011 as well as Faculty Achievement Award in Education (1993) and in Basic Research (1998 & 2017). In 2015, he was an awardee of the Simiao Sun Award for Biomedical Achievement, and an inaugural awardee of Breast Cancer Basic and Translational Research Outstanding Achievement Award in 2017 International Breast Cancer Stem Cell Symposium.

In 2018, he becomes the President-elect of The University of Texas Academy of Health Science Education. It is worth noting that Dr. Hung is a dedicated educator who persistently nurture next generation cancer biologists. In addition to graduating more than 55 Ph.D. students and directly supervising close to 200 postgraduate fellows, he is a recipient of prestigious educational awards including 2017 UT System Regents' Outstanding Teaching Award and John P. McGovern Outstanding Teacher Award University of Texas Health Science Center-Houston. Dr. Hung is the only faculty who receives the latter award four times.

Dr. Hung is a basic scientist with a keen translational vision and especially his recent research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. His laboratory has a long term commitment to the following research areas: 1) discovery of novel functionality of epidermal growth factor receptor (EGFR) family which may provide useful insight to understand cancer formation and development; 2) identification of crosstalks of signal pathways/networks in cancer cells and tumor microenvironment which could potentially predict resistance to target therapy; 3) development of marker-guided targeted therapy including PARP and EGFR inhibitors, immune checkpoint therapy which will effectively treat cancer patients.



, Ph.D., is currently an Associate Professor of Pathology at the University of California, San Diego. She first began her research career in the late 1990s as a virologist and obtained her doctorate from the University of Nebraska-Lincoln and Nankai University, followed by post-doctoral training at the Johns Hopkins University and Vanderbilt University. Before joining UCSD in 2016, Dr. Wang was an Assistant/Associate Professor of Cancer Biology at the Beckman Research Institute of the City of Hope. Dr. Wang is the recipient of a NIH K99/R00 Pathway to Independence Award and several R01 grants. She has also received several IDEA awards from the California Breast Cancer Research Program and an AACR-Breast Cancer Research Foundation translational award. Dr. Wang has more than 60 publications related to her research in cancer and viral oncology, including several recent publications related to extracellular miRNAs in *Nature Cell Biology*, *Cancer Cell*, and *Cell Metabolism*, etc. Her lab is currently exploring additional mechanisms through which cancer-derived extracellular miRNAs contribute to the multifaceted reprogramming of non-cancerous cells in the tumor microenvironment as well as novel therapeutic strategies targeting cancer-derived extracellular miRNAs for their function in cancer-host communication.



obtained his PhD degree from Clarkson University in USA, and accomplished his postdoctoral research training programs in Texas A&M University and Baylor College of Medicine. Dr. Xu has been a faculty member in the Department of Molecular and Cellular Biology (MCB) at Baylor College of Medicine since 1997. He currently holds a tenured full professor position in the Department of Molecular and Cellular Biology and the Director position in the Genetically Engineered Mouse Core Laboratory at Baylor College of Medicine. Right after the nuclear receptor coactivator (SRC) family genes were identified in 1990s, Dr. Xu was the first who carried out the initial studies that defined the physiological function of these nuclear receptor coactivators and their roles in mammary gland and prostate tumorigenesis by using knockout mouse models. Dr. Xu's current research interest is focused on understanding the roles and molecular mechanisms



, Professor and Chairman of Radiation Oncology Department, University of Arkansas for Medical Science.

Education: PhD, Cancer Biology, Harvard University, Boston, Ma/F1 9.960000447 0 540 7



is a Professor and the Chair ad interim of the Department of
Molecular and Cellular



Gen-

, Ph.D. is a Professor of Pathology and Molecular Biology at the University of California San Diego (UCSD). Dr. Feng's research program is centered on dissecting the anti-oncogenic effects of pro-oncogenic proteins in the liver recently identified by his group and others. His most recent findings may lead to development of a preventive strategy for liver cancer in a huge population of patients with chronic liver diseases, and an effective combination immunotherapy for advanced liver cancer patients by coordinated activation of innate and adaptive immunity.

Dr. Feng received Ph.D. degree from Indiana University Bloomington, and did postdoctoral work with Dr. Bryan Williams at the Hospital for Sick Children, and with Tony Pawson at the Mt Sinai Hospital in Toronto, Canada. Dr. Feng has published 172 peer-reviewed research papers, reviews and book chapters in Science, Nature Medicine, Cancer Cell, PNAS, Immunity, Nature Immunology, Genes & Deve, MCB, JBC. Blood, Hepatology, J Hepatology and J. Immunol, etc. Dr. Feng has served on the editorial boards of Molecular and Cellular Biology (MCB), Journal of Biological Chemistry (JBC), Hepatology, and Journal of Hepatology. In 2016, Dr. Feng was elected as Fellow of American Association for the Advancement of Science (AAAS).



Jin-Dan Yu
俞锦丹

Dr. Yu is currently a Professor of Medicine – Hematology/Oncology and Professor of Biochemistry and Molecular Genetics at the Northwestern University, Feinberg School of Medicine. Dr. Yu received a Bachelor of Medicine degree from Beijing Medical University (Peking University, Health Science Center) in 1998 and a Ph.D. degree in Biomedical Engineering from the University of Michigan – Ann Arbor in 2004. After completing postdoctoral training with HHMI (Howard Hughes Medical Institute) investigator Dr. Arul M. Chinnaiyan at the University of Michigan, Dr. Yu was recruited to join the faculty at Northwestern University Medical School in 2009, wherein she rapidly rose to the rank of Full Professor with Tenure in 2017. Dr. Yu is internationally recognized for her work on genomic and epigenomic regulations of prostate cancer, with strong focuses on androgen receptor (AR), FOXA1, and the Polycomb Group protein EZH2. Her research utilizes integrative genomics and bioinformatics approaches to understand the molecular mechanisms underlying prostate tumorigenesis. Dr. Yu has a strong interest in translating research from the bench to the bedside through the development of novel biomarkers for aggressive prostate cancer and of new treatment regimens for end-stage castration-resistant prostate cancer. Aligned with this, she is a Co-Director of the Translational Bridge Program at the Robert H. Lurie Comprehensive Cancer Center, supervising funding and awards for translational cancer projects. To date, Dr. Yu has published more than 60 peer-reviewed articles, a majority of which in Cell, Science, Nature, and AACR journals. Dr. Yu is an Associate Editor of Oncogene (IF 8.5), is on the Editorial Board of many other journals, and frequently reviews for prestigious journals such as Cancer Cell, Nature Genetics, Genome Research, Nature Communications, and Cancer Research. Dr. Yu has served on many NIH study sections, DOD review panels and review groups for other funding agencies nationally and internationally. Notably, she is currently a Standing Member of the NIH Cancer Etiology (CE) Study Section with her tenure starting in October 2018. Dr. Yu is passionate about the training of the next-generation scientists and has thus far trained 19 postdocs/fellows, 11 graduate students, and 11 undergraduate students in her own laboratory, and served on 19 PhD thesis committees. Dr. Yu is the Director of Ph.D. Training in Cancer Biology Cluster at Northwestern University Graduate School and was recently named the Assistant Director of Education and Training in the Robert H. Lurie Cancer Center. Dr. Yu has received several prestigious awards including the NIH K99/R00 Pathway to Independence Award, the Agilent Early-Career Professor Award, the DOD Impact Award, and the Prostate Cancer Foundation Challenge Award.



Burton B Yang
杨柏华
University of Toronto

finished his M.Sc. studies at the South China Agricultural University early 1985. He entered the Ph.D. program at the University of Manitoba in 1988 and received his Ph.D. degree in 1992. After two periods of postdoctoral training at the Manitoba Institute of Cell Biology and Harvard Medical School, Dr. Yang took a Scientist position at Sunnybrook Health Sciences Centre in 1995 and became an Assistant Professor at the Department of Laboratory Medicine and Pathobiology, University of Toronto. He was promoted to Associate Professor in 2001 and to Professor in 2007. During the past 20 years, he received a number of personal awards from the Arthritis Society of Canada, the Premier's Research Excellence Award, Canadian Institutes of Health Research New Investigator Award, CIHR-Ontario Women's Health Council/IGH Mid-Career Award, Career Investigator Award and Investigator Award from the Heart and Stroke Foundation of Canada. Dr. Yang has published 176 papers. Some of them are in high ranking journals including Nature Cell Biology, European Heart Journal, Cell Research, Nature Communications, PNAS. His papers have received over 12000 citations with an H-Index of 63 by Google Scholar.




Shi-Yong Sun
孙士勇
Emory University

, Ph.D. Department of Hematology and Medical Oncology, Emory Winship Cancer Institute and Emory University School of Medicine, Atlanta, GA, USA. Dr. Sun earned his Ph.D. in cancer pharmacology from Peking Union Medical College (PUMC)/Chinese Academy of Medical Sciences (CAMS) in 1990 and later received his postdoctoral training in cancer biology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, USA. Dr. Sun is currently a tenured Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine and Winship Cancer Institute in Atlanta, Georgia, USA. He is also a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar.

Dr. Sun's research primarily focuses on the following areas: 1) regulation of death receptors, particularly TRAIL receptors, by small therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy; 2) understanding mTOR signaling in cancer and targeting the mTOR axis for cancer therapy; and 3) understanding and overcoming acquired resistance to third generation EGFR inhibitors.

Dr. Sun is on the editorial boards of over 30 cancer-related journals and serves as Associate Editors for Molecular Cancer, Molecular Carcinogenesis and BMC Cancer. He has reviewed manuscripts for over 80 scientific journals and grants for over 10 international organizations including different NIH/NCI study sections and has published over 150 original research papers in prominent peer-reviewed journals.



YI LI
李毅
Baylor College of Medicine

Dr. Li's lab investigates the molecular and cellular mechanisms of breast cancer initiation and progression, with the goal of translating this knowledge into breast cancer prevention and treatment. His graduate studies were on molecular biology and microbiology, postdoctoral study under the mentorship of Dr. Harold Varmus provided training in cancer biology and mouse models of breast cancer. Dr. Yi Li's lab has made a number of significant contributions to the field of breast cancer: we pioneered an intraductal retroviral mouse model, RCAS/TVA, to closely recapitulate human breast tumorigenesis, discovered a molecular mechanism underlying the dichotomous effects of pregnancy on breast tumorigenesis, and established intermittent anti-STAT5 treatment for preventing breast cancer in preclinical models, which has resulted in a multi-center window-of opportunity clinical trial (TBCRC042).



Dr. Li's studies focus on signaling pathways that are activated by DNA damage-inducing agents. DNA damage activates a signaling cascade called DNA damage response (DDR) pathway that initiates DNA repair and cell cycle checkpoint activation. Understanding this pathway will help us understand the cause of genomic instability, a driving force of aging and cancer. Several progeroid genetic syndromes have also been linked to mutations of genes in this pathway, such as Bloom and Warner syndrome. He has been studying the DDR pathway for 18 years and has made unique contributions to the field. His studies help elucidate how DNA damage response factors such as ATM, MDC1, NBS1, 53BP1 and BRCA1 are assembled at the sites of DNA damage and help DNA repair. In addition, through proteomic approaches, they have identified novel factors involved in the DNA damage response downstream of ATM. Recently, his study focuses on the ubiquitination signaling pathway in cell cycle regulation and DNA repair. We have studied several E3 ubiquitin ligases (BRCA1, UHRF1, RNF4, Parkin, WSB1) and deubiquitinases (USP10, USP20, UCHL3) and characterized their role in cell cycle regulation, DNA repair, cellular metabolism and cancer metastasis. He has also studied the function of the E3 ubiquitin ligase complex containing BRCA1, UHRF1, RNF4, Parkin, WSB1, and deubiquitinases (USP10, USP20, UCHL3) and characterized their role in cell cycle regulation, DNA repair, cellular metabolism and cancer metastasis. He has also studied the function of the E3 ubiquitin ligase complex containing BRCA1, UHRF1, RNF4, Parkin, WSB1, and deubiquitinases (USP10, USP20, UCHL3) and characterized their role in cell cycle regulation, DNA repair, cellular metabolism and cancer metastasis.



Zhi-Yuan Shen

, PhD.

Current Positions (07/2008 – present)


- Professor of Radiation Oncology, Pharmacology
- Chief, Division of Radiation Cancer Biology, Department of Radiation Oncology, Robert Wood Johnson Medical School,
- Co-Leader, Genomic Instability and Cancer Genetics program, NCI designated comprehensive cancer center, Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey

Education and Training

- 02/1994-09/1996: Director's Postdoctoral Fellowship of Los Alamos National Laboratory, Los Alamos, New Mexico, USA
- 01/1990-02/1994: PhD (05/1993) and Postdoc (02/1994), radiation and molecular biology, Dept of Radiological Sciences, Colorado State University, Fort Collins, CO, USA (thesis advisor: Mortimer M. Elkind)
- 08/1985-08/1988: MS (radiation medicine and toxicology), Beijing Institute of Radiation Medicine, Beijing, China.
- 09/1980-08/1985: MD, Norman Bethune University of Medical Sciences (presently Jilin University School of Medicine), Jilin, China

Past Positions

- 05/2006 – 06/2008: Tenured Professor (07/2008-), Tenured Associate Professor (05/2006), inaugural Chief (05/2006 -) of Division of Radiation Cancer Biology at Department of Radiation Oncology, and Co-leader (12/2008-) of Genomic Instability and Cancer Genetics program, NCI Designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey. Rutgers University
- 05/2000 - 05/2006: Tenured Associate professor (07/2003-05/2006), Tenure-track Assistant Professor (2000-2003), and Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM
- 05/1997 - 05/2000: Tenure-track Assistant Professor, Cancer Center and Department of Molecular Genetics, University of Illinois at Chicago, Chicago, IL.
- 09/2016 – 05/1997: Staff Scientist, Los Alamos National Laboratory, New Mexico, USA



Chu-Xia Deng
邓初夏
University of Macau

Professor obtained his master degree of science in the Institute of Hydrobiology, Chinese Academia of Science in 1984 and Ph.D degree in the Department of Biology, University of Utah in 1992, respectively. As a PhD student, Deng studied with professor Mario R. Capecchi, a co-winner of the Nobel Prize in Physiology or Medicine in 2007. After finishing his postdoctoral training in the Harvard Medical School in 1995, he became a Tenure-Track Investigator, then the Tenured-Investigator and the Chief of the Mammalian Genetics Section at the United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of National Institutes of Health (NIH). His current position is the Dean of Faculty of Health Sciences, University of Macau.

Over the past two decades, the research team led by Professor Deng has made Significant contributions to research on cancer and metabolic diseases, ageing, cancer stem cells, particularly in the underlying mechanisms for BRCA1 associated breast cancer. These data have attained important results that have attracted worldwide attention. He and his team have published over 370 papers including over 40 in Cell, Nature, Science and their sister journals, with a total citation of >57,000 times and a H-index of 128 by Google Scholar.

Professor Deng received the NIH-APAO Outstanding Achievement Award (2000, NIH, USA), Outstanding Oversea Scholar from National Science Foundation (2002, China), NIDDK "You Make A Difference Award" (2005, 2013), and NIDDK Director's Award (2011). He was elected as a Fellow of the American Association for the Advancement of Sciences (AAAS) in 2012.


2000 2007
2008-2013
2013
Cell PNAS 20

-

1.Ke H#, Zhao L#, Zhang H#, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, Wang L, Wu C, Wang Y, Nie J, Jiao B*, 2018.Loss



Cai-Xia Guo
郭彩霞
中科院北京基因组研究所



Tie Jing-ang

1991

1999-2004

2004-2009

2009

1999

DNA

Cell Molecular Cell PNAS Nature

Communication

